CFM
ORKA

Cornerstone Financial Management’s Oruka Therapeutics ORKA Stock Holding History

Cornerstone Financial Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2K Hold
21
– – ﹤0.01% 851
2026
Q1 		$1.03K Hold
21
– – ﹤0.01% 967
2025
Q4 		$637 Buy
+21
New +$585 ﹤0.01% 1076

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Cornerstone Financial Management's ORKA Position: Q2 2026 in Review

Cornerstone Financial Management held its Oruka Therapeutics (ORKA) position steady in Q2 2026 at 21 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #851.

Cornerstone Financial Management first reported a position in ORKA in Q4 2025 and has held it in 3 quarters since. 255 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Cornerstone Financial Management held 21 shares of Oruka Therapeutics worth $2K as of Q2 2026.
  • Cornerstone Financial Management left its Oruka Therapeutics share count unchanged in Q2 2026.
  • Oruka Therapeutics made up ﹤0.01% of Cornerstone Financial Management's portfolio in Q2 2026, its #851 holding.
  • Cornerstone Financial Management first reported a position in Oruka Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 255 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Cornerstone Financial Management's 13F filing for Q2 2026, filed 12 Aug 2026.